In last trading session, Werewolf Therapeutics Inc (NASDAQ:HOWL) saw 0.61 million shares changing hands with its beta currently measuring 0.37. Company’s recent per share price level of $1.59 trading at $0.02 or 1.27% at ring of the bell on the day assigns it a market valuation of $70.85M. That closing price of HOWL’s stock is at a discount of -415.09% from its 52-week high price of $8.19 and is indicating a premium of 13.21% from its 52-week low price of $1.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.33 million shares which gives us an average trading volume of 746.75K if we extend that period to 3-months.

For Werewolf Therapeutics Inc (HOWL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.28 in the current quarter.

Werewolf Therapeutics Inc (NASDAQ:HOWL) trade information

Upright in the green during last session for gaining 1.27%, in the last five days HOWL remained trading in the red while hitting it’s week-highest on Monday, 12/16/24 when the stock touched $1.59 price level, adding 7.56% to its value on the day. Werewolf Therapeutics Inc’s shares saw a change of -58.81% in year-to-date performance and have moved -3.64% in past 5-day. Werewolf Therapeutics Inc (NASDAQ:HOWL) showed a performance of -3.05% in past 30-days. Number of shares sold short was 1.23 million shares which calculate 2.09 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 86.75% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would drop -654.72% in reaching the projected high whereas dropping to the targeted low would mean a loss of -654.72% for stock’s current value.

Werewolf Therapeutics Inc (HOWL) estimates and forecasts

Statistics highlight that Werewolf Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -39.08% of value to its shares in past 6 months, showing an annual growth rate of -48.57% while that of industry is 17.40. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -90.57% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 301.59k for the same. And 4 analysts are in estimates of company making revenue of 375k in the next quarter. Company posted 1.5M and 742k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -13.31% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -46.19% while estimates for its earnings growth in next 5 years are of 10.90%.

Werewolf Therapeutics Inc (NASDAQ:HOWL)’s Major holders

RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at HOWL for having 6.14 million shares of worth $14.99 million. And as of 2024-06-30, it was holding 14.7688 of the company’s outstanding shares.

The second largest institutional holder is MPM ASSET MANAGEMENT LLC, which was holding about 4.28 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.2967 of outstanding shares, having a total worth of $10.45 million.